- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04977336
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
February 16, 2023 updated by: Vertex Pharmaceuticals Incorporated
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after a bunionectomy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
274
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Sheffield, Alabama, United States, 35660
- Shoals Medical Trials Inc.
-
-
Arizona
-
Phoenix, Arizona, United States, 85053
- Arizona Research Center
-
-
California
-
Anaheim, California, United States, 92801
- Anaheim Clinical Trials
-
Pasadena, California, United States, 91105
- Lotus Clinical Research
-
Tarzana, California, United States, 91356
- New Hope Research Development
-
-
Georgia
-
Atlanta, Georgia, United States, 30331
- Atlanta Center for Medical Research
-
-
Maryland
-
Pasadena, Maryland, United States, 21122
- Chesapeake Research Group
-
-
Ohio
-
Dayton, Ohio, United States, 45417
- Midwest Clinical Research Center
-
-
Texas
-
Bellaire, Texas, United States, 77401
- First Surgical Hospital
-
Carrollton, Texas, United States, 75006
- Legent Orthopedic Hospital
-
San Antonio, Texas, United States, 78229
- Endeavor Clinical Trials
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- JBR Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
Before Surgery:
- Participant scheduled to undergo a primary unilateral bunionectomy with distal first metatarsal osteotomy (i.e., Austin procedure) and internal fixation under regional anesthesia (Mayo and popliteal sciatic block)
After Surgery:
- Participant is lucid and able to follow commands
- All analgesic guidelines were followed during and after the bunionectomy
Key Exclusion Criteria:
Before Surgery:
- Prior history of bunionectomy or other foot surgery on the index foot
- History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
- Any prior surgery within 1 month before the first study drug
After Surgery:
- Participant had a Type 3 deformity requiring a base wedge osteotomy or concomitant surgery such as hammertoe repair, or had medical complications during the bunionectomy that, in the opinion of the investigator, should preclude randomization
Other protocol defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VX-548
Participants will be randomized to receive different dose levels of VX-548.
|
Tablets for oral administration.
Placebo matched to HB/APAP for oral administration.
|
Placebo Comparator: Placebo
Participants will receive placebos matched to VX-548 and HB/APAP.
|
Placebo matched to HB/APAP for oral administration.
Placebo matched to VX-548 for oral administration.
|
Active Comparator: Hydrocodone bitartrate/acetaminophen (HB/APAP)
Participants will receive HB/APAP.
|
Capsules for oral administration.
Placebo matched to VX-548 for oral administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time-weighted sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug
Time Frame: 0 to 48 Hours After the First Dose of Study Drug
|
0 to 48 Hours After the First Dose of Study Drug
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time-weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug
Time Frame: 0 to 24 Hours After the First Dose of Study Drug
|
0 to 24 Hours After the First Dose of Study Drug
|
Proportions of Participants With >=30 Percent (%), >=50%, and >=70% Reduction in NPRS at 48 Hours After the First Dose of Study Drug
Time Frame: At 48 Hours After the First Dose of Study Drug
|
At 48 Hours After the First Dose of Study Drug
|
Maximum Observed Plasma Concentration (Cmax) of VX-548
Time Frame: Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug
|
Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of VX-548
Time Frame: Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug
|
Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug
|
Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-548
Time Frame: Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug
|
Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug
|
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Day 1 up to Day 18
|
Day 1 up to Day 18
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 19, 2021
Primary Completion (Actual)
February 17, 2022
Study Completion (Actual)
March 4, 2022
Study Registration Dates
First Submitted
July 15, 2021
First Submitted That Met QC Criteria
July 15, 2021
First Posted (Actual)
July 26, 2021
Study Record Updates
Last Update Posted (Estimate)
February 27, 2023
Last Update Submitted That Met QC Criteria
February 16, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VX21-548-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Pain
-
Rajavithi HospitalCompletedTotal Abdominal Hysterectomy ,Pain , Acute Postoperative,Gabapentin , CelecoxibThailand
-
Seoul National University HospitalNot yet recruiting
-
Chung-Ang University Gwangmyeong HospitalRecruitingPostoperative Pain, AcuteKorea, Republic of
-
TC Erciyes UniversityCompletedPostoperative Pain, AcuteTurkey
-
Zagazig UniversityRecruiting
-
Mansoura UniversityRecruitingPostoperative Pain, AcuteEgypt
-
University of California, San DiegoActive, not recruitingPostoperative Pain, AcuteUnited States
-
Umraniye Education and Research HospitalNot yet recruiting
-
Sohag UniversityCompletedPostoperative Pain, AcuteEgypt
-
Cairo UniversityNot yet recruitingPostoperative Pain, Acute
Clinical Trials on VX-548
-
Vertex Pharmaceuticals IncorporatedRecruiting
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedRecruitingPainful Lumbosacral RadiculopathyUnited States
-
Vertex Pharmaceuticals IncorporatedCompletedAcute PainUnited States
-
Vertex Pharmaceuticals IncorporatedCompletedAcute PainUnited States
-
Vertex Pharmaceuticals IncorporatedCompletedAcute PainUnited States
-
Vertex Pharmaceuticals IncorporatedCompleted